Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
BioLineRx, Ltd.
BioLineRx in-licenses BL-3010 from Gevys for the treatment of pain
June 23rd, 2006
BioLineRx, Ltd., a drug development company in Israel, has signed an exclusive worldwide licensing agreement with Gevys Pharmaceuticals, Ltd., for the development and commercialization of BL-3010, a novel approach for the treatment of acute and chronic pain. Gevys's patented technology utilizes a combination of approved drugs to dramatically increase the potency of micro-doses of classical pain medications. The result is that BL-3010 will deliver effective pain relief with significant reductions in toxicity and side effects. "We are pleased to license this proprietary technology from Gevys, and the advancement of the program highlights our commitment...
Source: Biotech Law Weekly (2006-06-23)
|
